{"nctId":"NCT01391286","briefTitle":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis","startDateStruct":{"date":"2011-07-01","type":"ACTUAL"},"conditions":["Eyelash Hypotrichosis"],"count":36,"armGroups":[{"label":"bimatoprost solution 0.03%","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost solution 0.03%"]},{"label":"bimatoprost vehicle solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: bimatoprost vehicle solution"]}],"interventions":[{"name":"bimatoprost solution 0.03%","otherNames":["LATISSEÂ®"]},{"name":"bimatoprost vehicle solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have inadequate eyelashes due to chemotherapy treatment\n* Treated for solid tumors such as breast or colorectal cancer in early stages where the cancer has not spread outside the primary organ (eg, stage 1, 2 or 3a for breast cancer)\n* Have completed chemotherapy treatment for at least 4 weeks but not more than 24 weeks and all side effects related to chemotherapy are recovered, improved or maintained, with the exception of hair loss\n\nExclusion Criteria:\n\n* Any disease/infection/abnormality of the eye or area around the eye\n* Any ocular surgery within 3 months or anticipated need for ocular surgery during the study\n* Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes\n* Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months\n* Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products\n* Use of treatments which may affect hair growth (eg, minoxidil) within 6 months except for prior chemotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)","description":"The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)","description":"Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":"1.397"},{"groupId":"OG001","value":"5.00","spread":"1.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"1.574"},{"groupId":"OG001","value":"0.6","spread":"1.317"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Thickness as Measured by DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm\\^2). A positive change from Baseline indicated fuller eyelashes (improvement).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.456"},{"groupId":"OG001","value":"0.45","spread":"0.294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.460"},{"groupId":"OG001","value":"0.25","spread":"0.393"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyelash Darkness as Measured by DIA","description":"Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140.15","spread":"21.855"},{"groupId":"OG001","value":"144.98","spread":"18.561"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.40","spread":"12.666"},{"groupId":"OG001","value":"-10.03","spread":"18.248"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Radiation skin injury","Nasopharyngitis","Skin hyperpigmentation","Eye pruritus","Arthralgia"]}}}